ABIOMED, Inc. (NASDAQ:ABMD) price target lowered to $461.00 by Morgan Stanley

ME Staff
-
0

Analyst Ratings For ABIOMED, Inc. (NASDAQ:ABMD)

Today, Morgan Stanley lowered its price target on ABIOMED, Inc. (NASDAQ:ABMD) to $461.00 per share.

There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on ABIOMED, Inc. (NASDAQ:ABMD) is Buy with a consensus target price of $391.6250 per share, a potential 24.50% upside.

Some recent analyst ratings include

  • 11/2/2018-ABIOMED, Inc. (NASDAQ:ABMD) gets upgraded to Buy by BTIG Research with a price target of $450.00
  • 4/4/2018-ABIOMED, Inc. (NASDAQ:ABMD) has coverage initiated with a Buy ➝ Buy rating and $332.00 price target
  • 2/16/2018-ABIOMED, Inc. (NASDAQ:ABMD) had its Buy rating reiterated by SunTrust Banks with a $370.00 price target
  • On 9/25/2018 Michael G Howley, VP, sold 10,000 with an average share price of $432.50 per share and the total transaction amounting to $4,325,000.00.
  • On 8/29/2018 Andrew J Greenfield, VP, sold 4,440 with an average share price of $395.00 per share and the total transaction amounting to $1,753,800.00.
  • On 7/30/2018 David M Weber, COO, sold 19,282 with an average share price of $356.77 per share and the total transaction amounting to $6,879,239.14.
  • On 6/21/2018 Michael R Minogue, Chairman, sold 105,000 with an average share price of $439.69 per share and the total transaction amounting to $46,167,450.00.
  • On 6/18/2018 David M Weber, COO, sold 46,500 with an average share price of $442.63 per share and the total transaction amounting to $20,582,295.00.
  • On 5/8/2018 Martin P Sutter, Director, sold 21,890 with an average share price of $343.50 per share and the total transaction amounting to $7,519,215.00.
  • On 5/7/2018 Michael G Howley, VP, sold 17,500 with an average share price of $348.11 per share and the total transaction amounting to $6,091,925.00.

About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Recent Trading Activity for ABIOMED, Inc. (NASDAQ:ABMD)
Shares of ABIOMED, Inc. closed the previous trading session at 314,05 −10,99 3,38 % with 315.94 shares trading hands.